
Opinion|Videos|February 26, 2024
Treatment Practices for Castration-Sensitive Prostate Cancer
The Oncology Brothers and Rana R. McKay, MD, have a comprehensive discussion on the treatment of patients with castration-sensitive prostate cancer.
Advertisement
Advertisement
Related to this article

At CFS 2026, Martin Gleave, CM, MD, FRCSC, FACS, explained why higher-volume, high-grade prostate cancer is the sweet spot for perioperative ARPI therapy.

The FDA granted breakthrough therapy designation to 64Cu-SAR-bisPSMA for PSMA PET imaging in men with suspected biochemical recurrence of prostate cancer.

Martin Gleave, CM, MD, FRCSC, FACS, discussed perioperative therapy selection, the GUNS trial, and postoperative radiotherapy in prostate cancer.

Martin Gleave, CM, MD, FRCSC, FACS, explained how the GUNS trial is using tumor genomics to guide neoadjuvant therapy in high-risk prostate cancer.

The ACS now recommends biennial PSA screening for average-risk men aged 50 to 69 years and annual screening from age 45 for Black men.

NCCN guidelines now list the ArteraAI Prostate Test for risk stratification in patients with biochemical recurrence after radical prostatectomy.

A dual bispecific regimen of pasritamig and JNJ-9401 reduced PSA by at least 50% in 73% of heavily pretreated patients with metastatic CRPC.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Neladalkib in Advanced ALK+ Non–Small Cell Lung Cancer
2
64Cu-SAR-bisPSMA Earns FDA Breakthrough Designation in Recurrent Prostate Cancer
3
Selecting Patients With High-Risk Prostate Cancer for Perioperative ARPI Therapy
4
Lung Cancer Survival Rate Climbs to 31%, Although Screening Gaps Persist
5

